Tango Therapeutics Inc (TNGX)
Healthcare
Biotechnology
—
27.20 $
-1.4%
vs. previous close
Closing price · As of: 31. Jul 2026
Tango Therapeutics Inc (TNGX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -139 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| -25 | 70 | -60 | -109 | -118 | -132 | -139 | |
| 0.6 | 0.7 | 0.9 | 1.6 | 2.4 | 2.5 | 2.3 | |
| 1.7 | 1.8 | 7.8 | 14 | 19 | 29 | 26 | |
| 2.2 | 2.7 | 9.2 | 14 | – | – | – | |
| 1.7 | 119 | -11 | -18 | -38 | -32 | -67 | |
| 1.8 | 1.1 | 1.8 | 7.7 | 1.5 | 0.8 | 1.0 | |
| 0.8 | -145 | -183 | 26 | 41 | 86 | -41 | |
| – | – | 31 | – | – | – | – | |
| – | – | 342 | 0.0 | – | – | – | |
| 11 | 81 | 357 | 1.6 | 82 | 48 | 223 | |
| 25 | 5.5 | 114 | -81 | 5.9 | 2.3 | 43 | |
| -27 | 69 | -61 | -117 | -120 | -132 | -140 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.